Influence of race or ethnicity on pharmacokinetics of drugs

Journal of Pharmaceutical Sciences
J A Johnson

Abstract

Review of the current literature on racial differences in pharmacokinetics of drugs supports the premise that only pharmacokinetic processes which are biologically or biochemically mediated have the potential to exhibit differences between racial or ethnic groups. Thus, the pharmacokinetic factors which can be expected to potentially exhibit racial differences are (1) bioavailability for drugs which undergo gut or hepatic first-pass metabolism, (2) protein binding, (3) volume of distribution, (4) hepatic metabolism, and (5) renal tubular secretion. Absorption (unless active), filtration at the glomerulus, and passive tubular reabsorption would not be expected to exhibit racial differences. As is evident from this review, there are relatively few drugs for which there is information on ethnic or racial differences in pharmacokinetics. Thus it is often necessary to try to predict whether such differences might exist. Taking into consideration the above factors and evaluation of the pharmacokinetic characteristics of the drug, it should be possible to identify those drugs most likely to exhibit differences in their pharmacokinetics. For example, a drug which is eliminated entirely by the kidneys through filtration and reabsorption...Continue Reading

References

Dec 1, 1992·Clinical Pharmacology and Therapeutics·M V RellingW E Evans
May 1, 1992·Clinical Pharmacology and Therapeutics·J A Johnson, B S Burlew
May 1, 1991·Clinical Pharmacokinetics·A J Wood, H H Zhou
Jul 1, 1990·Clinical Pharmacology and Therapeutics·H H ZhouG R Wilkinson
Jan 13, 1989·JAMA : the Journal of the American Medical Association·C K Svensson
Apr 1, 1984·British Journal of Clinical Pharmacology·M V RudorferW Z Potter
Jun 1, 1981·Clinical Pharmacology and Therapeutics·M M GhoneimK O Kayaba
May 1, 1995·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·S A AbramsJ E Stuff
Jun 1, 1995·Clinical Pharmacology and Therapeutics·K M SowinskiJ A Johnson
Nov 1, 1994·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·M E Kitler
Jan 1, 1995·Irish Journal of Medical Science·S J HosseineJ Feely
Nov 1, 1993·Clinical Pharmacology and Therapeutics·H H ZhouA J Wood
Jan 1, 1994·Clinical Pharmacology and Therapeutics·H L McLeodW E Evans
Sep 1, 1993·Clinical Pharmacology and Therapeutics·C H AhsanM Amanullah
Jan 1, 1995·Drug Metabolism Reviews·T I Edeki, D A Brase
Aug 1, 1996·Clinical Pharmacology and Therapeutics·Y CaracoA J Wood
Jan 1, 1996·British Journal of Clinical Pharmacology·M T KinironsA J Wood
Jan 1, 1997·European Journal of Clinical Pharmacology·J A Johnson, T N Livingston

❮ Previous
Next ❯

Citations

Apr 9, 2002·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Brigette MaPhilip J Johnson
Jun 2, 2005·Nature Reviews. Cancer·Samir D UndeviaMark J Ratain
Jun 26, 2001·British Journal of Clinical Pharmacology·E ChanS S Hue
May 3, 2002·The New England Journal of Medicine·Allen L GiffordUNKNOWN HIV Cost and Services Utilization Study Consortium
Feb 28, 2006·Journal of Palliative Medicine·LaVera M Crawley
Apr 26, 2003·Heart Disease·Benjamin M SchaeferPamela Charney
Feb 1, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·K F TamH Y S Ngan
Apr 15, 2004·Journal of Medical Ethics·P Allmark
Nov 8, 2001·Journal of Clinical Pharmacology·M H MageeW J Jusko
Feb 25, 1999·Pharmacotherapy·M H MohamedJ A Johnson
Aug 10, 2002·Clinical Pharmacokinetics·Melton AffrimeMitchell Cayen
Aug 23, 2002·Clinical Pharmacokinetics·Uwe ChristiansAlfonso Lampen
Jun 27, 2013·Journal of Pharmaceutical Sciences·Tonika Bohnert, Liang-Shang Gan
Feb 13, 2014·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Oscar A LinaresRaymond C Boston
Dec 1, 2009·The Journal of Pain : Official Journal of the American Pain Society·Karen O AndersonRichard Payne
Sep 3, 2004·Journal of Clinical Pharmacology·Kiman KimHartmut Derendorf
Sep 16, 2003·Journal of Clinical Pharmacology·Thorir D BjornssonCaroline Loew
Aug 8, 2009·British Journal of Clinical Pharmacology·Zheng JiaoMing-kang Zhong
Aug 5, 2003·British Journal of Clinical Pharmacology·Korbtham SathirakulStephen D Wise
Jan 31, 2007·The American Journal of Cardiology·James K Liao
Feb 8, 2005·American Journal of Obstetrics and Gynecology·Annie YessaianWendy R Brewster
Apr 10, 2012·Best Practice & Research. Clinical Gastroenterology·E L D de Mare-Bredemeijer, H J Metselaar
Nov 12, 2014·Clinical Pharmacokinetics·Danny TsaiJason A Roberts
Jun 22, 2012·Pain·Barbara A HastieRoger B Fillingim
Jan 21, 2017·Clinical Pharmacokinetics·Maud A S WeerinkPieter Colin
Apr 30, 2017·Pediatrics International : Official Journal of the Japan Pediatric Society·Tsuyoshi KanekoTakeshi Higuchi
Feb 23, 2017·Antimicrobial Agents and Chemotherapy·Dong-Hwan LeeSungmin Kiem
Jan 11, 2019·Clinical Pharmacology in Drug Development·Ronald KongNeil Almstead
May 28, 2019·Cancer Chemotherapy and Pharmacology·Aurélie PétainPierre Ferré
Sep 13, 2013·The Cochrane Database of Systematic Reviews·Weiya ZhangHywel C Williams

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.